Shandong Xinhua Pharmaceutical Company Limited

HKSE 0719.HK

Shandong Xinhua Pharmaceutical Company Limited Current Liabilities for the year ending December 31, 2023: USD 350.15 M

Shandong Xinhua Pharmaceutical Company Limited Current Liabilities is USD 350.15 M for the year ending December 31, 2023, a -23.50% change year over year. Current liabilities are obligations that are expected to be settled within one year, including accounts payable, short-term debt, and other current liabilities.
  • Shandong Xinhua Pharmaceutical Company Limited Current Liabilities for the year ending December 31, 2022 was USD 457.70 M, a 16.24% change year over year.
  • Shandong Xinhua Pharmaceutical Company Limited Current Liabilities for the year ending December 31, 2021 was USD 393.75 M, a 7.94% change year over year.
  • Shandong Xinhua Pharmaceutical Company Limited Current Liabilities for the year ending December 31, 2020 was USD 364.78 M, a 2.20% change year over year.
  • Shandong Xinhua Pharmaceutical Company Limited Current Liabilities for the year ending December 31, 2019 was USD 356.92 M, a 4.01% change year over year.
Key data
Date Current Liabilities Total Non-Current Liabilities Shareholders' Equity Long-Term Debt
Market news
Loading...
SV Wall Street
HKSE: 0719.HK

Shandong Xinhua Pharmaceutical Company Limited

CEO Mr. Tongqing He
IPO Date Dec. 31, 1996
Location China
Headquarters Chemical Industry Area
Employees 7,104
Sector Healthcare
Industries
Description

Shandong Xinhua Pharmaceutical Company Limited, through its subsidiaries, develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products. It operates through Chemical bulk drugs, Preparations, and Chemical intermediates and Others segments. The company offers active pharmaceutical ingredients, pharmaceutical preparations, and chemical products, such as antipyretic analgesics; drugs for cardiovascular and cerebrovascular diseases; anti-infectives; drugs for diseases related to the central nervous system; and other drugs under the Xinhua brand. It also provides prepared Chinese herbal medicine decoction, traditional Chinese medicines, chemical preparations, antibiotics, biochemical medicines, chemical bulk drugs, anesthetics, anti-psychotic drugs, pharmaceutical precursor chemicals, protein assimilation preparations, peptide hormones, medical toxic drugs, etc.; and chemical raw materials, such as dimethyl sulfate, isobutylbenzene, 1,8-diazabicyclo, undec-7-ene, and tetramethylguanidine. In addition, the company offers materials and intermediates, powders for injection and tablets; tablets, hard capsules, granules, and dry suspension; imports and exports goods and technologies; designs medical projects; and health products research and development activities. Further, it engages in the certification business; electrical equipment engineering; and installation and testing of chemical equipment and electrical equipment, as well as the sale of mechanical, hardware, and electrical equipment. Additionally, the company produces and sells high-end steroid system APIs and intermediates; and provides internet data, internet sells, and internet information services for pharmaceuticals and medical devices, etc. It operates in the People's Republic of China, the Americas, Europe, and internationally. Shandong Xinhua Pharmaceutical Company Limited was founded in 1943 and is based in Zibo, the People's Republic of China.

Similar companies

1108.HK

Luoyang Glass Company Limited

USD 0.49

2.20%

0553.HK

Nanjing Panda Electronics Company Limited

USD 0.42

0.35%

0187.HK

Beijing Jingcheng Machinery Electric Company Limited

USD 0.39

1.72%

0874.HK

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited

USD 2.27

-0.52%

StockViz Staff

February 10, 2025

Any question? Send us an email